All Stories

AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases

AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.

Jun 13, 2025 - 12:20
 0
AstraZeneca pens $5.3B pact to use CSPC's AI platform to develop oral drugs for chronic diseases
AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases.
Read More

Tags:

Previous Article

Sam Luscombe takes MD seat at Luscombe Motors as Robin steps back

Next Article

Astellas offers lab space to startups to help Japanese biotechs 'go global'

Related Posts

Roche links BTK inhibitor to low relapse rate across 96-week multiple sclerosis trial

Roche links BTK inhibitor to low relapse rate across 96...

May 30, 2025  0

ASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study

ASCO: Actuate's pancreatic cancer drug boosts survival ...

Jun 2, 2025  0

Former Inhibikase leader launches new biotech for midstage Parkinson’s asset

Former Inhibikase leader launches new biotech for midst...

May 12, 2025  0